Northern Trust Corp Takes $218,000 Position in Affimed (NASDAQ:AFMD)

Northern Trust Corp purchased a new position in shares of Affimed (NASDAQ:AFMD) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 183,118 shares of the biopharmaceutical company’s stock, valued at approximately $218,000. Northern Trust Corp owned about 1.14% of Affimed as of its most recent filing with the Securities and Exchange Commission (SEC).

Separately, Intellectus Partners LLC raised its stake in Affimed by 34.0% during the fourth quarter. Intellectus Partners LLC now owns 126,414 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 32,053 shares during the period. Hedge funds and other institutional investors own 30.82% of the company’s stock.

Affimed Price Performance

Shares of NASDAQ AFMD opened at $0.18 on Tuesday. Affimed has a 12-month low of $0.07 and a 12-month high of $8.95. The stock has a 50 day simple moving average of $0.58 and a 200-day simple moving average of $1.12. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13.

Analysts Set New Price Targets

A number of brokerages have commented on AFMD. Leerink Partnrs downgraded Affimed from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Cantor Fitzgerald lowered Affimed from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, May 14th. Wall Street Zen initiated coverage on Affimed in a research note on Monday, May 19th. They set a “sell” rating for the company. HC Wainwright lowered Affimed from a “buy” rating to a “neutral” rating in a research report on Wednesday, May 14th. Finally, Leerink Partners reiterated a “market perform” rating and issued a $0.39 target price (down from $5.00) on shares of Affimed in a research note on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $7.90.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.